正揚生醫科技公司於103年5月15日公告其轉投資公司Amber BioLife Inc.與Cambium Medical Technologies,LLC(USA)簽訂合約共同開發乾眼症新藥及幹細胞培養液之內容涉有不實,經查違反櫃買中心「證券商營業處所買賣興櫃股票審查準則」第34條第8項規定,櫃買中心爰依興櫃審查準則第47條規定處以3萬元之違約金,並請公司應予更正。
This entry passed through the Full-Text RSS service - if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.
You are receiving this email because you subscribed to this feed at blogtrottr.com.